Five years after its formation, the Clinical and Translational Science Award (CTSA) at the Univeristy of North Carolina at Chapel Hill (UNC), the North Carolina Translational and Clinical Sciences Institute (NC TraCS), has become the integrated, campus-wide home for clinical and translational research at UNC. The overall goal of this U54 Cooperative Agreement application is to combine the research strengths, resources and opportunities at UNC and new partner, RTI International (RTI), to build on the foundation established in the CTSA's last five years. NC TraCS will work to improve human health by accelerating clinical and translational research from health science discovery to dissemination to patients and communities. NC TraCS will strive to overcome the well-documented barriers to the effective, sustained translation of research discovery along the translational research continuum by improving efficiency, training a research workforce and exporting successful, validated methods developed in NC TraCS to other CTSA institutions and the public. The proposed CTSA will specifically (1) amplify a thriving CTSA program to the point that it supports the full spectrum of clinical and translational research;(2) leverage CTSA resources and institutional strengths to create a critical, sustained focus on three strategic initiatives: (a) next-generation technologies to transform the very nature of clinical research and practice, (b) new paradigms and resources to accelerate drug development, and (c) robust comparative effectiveness research studies to provide definitive evidence of the benefits and harms of tests and treatments;and (3) train, support and incentivize the next generation of clinical and translational science researchers. These goals will be accomplished by three resources, six services, integrated and streamlined from the original 11, and the three strategic initiatives. UNC and RTI now have a unique set of research and training resources to support the full range of clinical and translational research, from basic science to clinical application to policy change. NC TraCS will leverage the opportunity of this CTSA application to garner >$60 million dollars in matching institutional support to extend our capabilities to meet the three aims. In partnership with RTI, NC TraCS will take advantage of the resources it has created and nourished during the past five years to quickly and effectively bring the fruits of research to patients across the state, as well as nationally through the CTSA Consortium.
Researchers, clinicians and health policy experts have long lamented the well-documented lag between basic science discoveries and when those discoveries reach patients to treat them and make their lives better. The proposed UNC-RTI partnership in cooperation with the CTSA Consortium will help to ensure that patients will more quickly and effectively benefit from the results of biomedical research.
|Hu, Quanyin; Qian, Chenggen; Sun, Wujin et al. (2016) Engineered Nanoplatelets for Enhanced Treatment of Multiple Myeloma and Thrombus. Adv Mater 28:9573-9580|
|Rao, Shangbang; Ibrahim, Joseph G; Cheng, Jian et al. (2016) SR-HARDI: Spatially Regularizing High Angular Resolution Diffusion Imaging. J Comput Graph Stat 25:1195-1211|
|Van Rie, Annelies; Sawry, Shobna; Link-Gelles, Ruth et al. (2016) Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome in children. Pediatr Pulmonol 51:157-64|
|Taitt, Chris Rowe; Anderson, George P; Ligler, Frances S (2016) Evanescent wave fluorescence biosensors: Advances of the last decade. Biosens Bioelectron 76:103-12|
|Guntas, Gurkan; Lewis, Steven M; Mulvaney, Kathleen M et al. (2016) Engineering a genetically encoded competitive inhibitor of the KEAP1-NRF2 interaction via structure-based design and phage display. Protein Eng Des Sel 29:1-9|
|Montgomery, Nathan D; Parker, Joel S; Eberhard, David A et al. (2016) Identification of Human Papillomavirus Infection in Cancer Tissue by Targeted Next-generation Sequencing. Appl Immunohistochem Mol Morphol 24:490-5|
|Wang, Chao; Sun, Wujin; Wright, Grace et al. (2016) Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody. Adv Mater 28:8912-8920|
|Henry, R R; Buse, J B; Wu, H et al. (2015) Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials. Diabetes Obes Metab 17:560-5|
|Zhu, Hongtu; Ibrahim, Joseph G; Chen, Ming-Hui (2015) Diagnostic Measures for the Cox Regression Model with Missing Covariates. Biometrika 102:907-923|
|Ferslew, Brian C; Xie, Guoxiang; Johnston, Curtis K et al. (2015) Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis. Dig Dis Sci 60:3318-28|
Showing the most recent 10 out of 18 publications